相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1751
进行中（未招募）
1
25.0%
已完成
2
50.0%
Unknown
1
25.0%
暂无批准数据
- The NIHR Newcastle Commercial Research Delivery Centre recruited the world's first patient to a major commercial study evaluating a novel treatment for chronic obstructive pulmonary disease (COPD). - The first participant was recruited within 103 days, significantly ahead of the UK government's target to reduce commercial trial setup times to under 150 days. - The study is investigating whether a new medicinal product can reduce airway inflammation, improve lung function, and prevent exacerbations by reducing mucus build-up in COPD patients. - This achievement demonstrates the value of the NIHR-ABPI partnership in creating a modern, coordinated research infrastructure that strengthens the UK's competitiveness in life sciences.
- Newcastle Hospitals successfully completed the UK's first implantation of the EASEE device, a pioneering brain stimulation implant developed by German company Precisis for treating focal epilepsy. - The procedure, performed by neurosurgeon Chris Cowie in under an hour, offers hope for patients with drug-resistant epilepsy in brain regions too risky for surgical removal. - The device uses dual stimulation methods to reduce seizure activity and has demonstrated effectiveness in reducing seizure severity and incidence in European patients. - With approximately 630,000 people living with epilepsy in the UK and 450 requiring risky brain surgery annually, this innovation represents a significant therapeutic advancement.
